Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
Cilli et al.
, Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
, Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Retrospective 46 idiopathic pulmonary fibrosis patients with COVID-19 in Turkey, showing lower mortality with favipiravir in unadjusted results, without statistical significance.
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
risk of death, 37.5% lower, RR 0.62, p = 0.51, treatment 5 of 23 (21.7%), control 8 of 23 (34.8%), NNT 7.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cilli et al., 3 Mar 2022, retrospective, Turkey, peer-reviewed, 10 authors.
Abstract: Respir. Med and Res 81 (2022) 100900
Available online at
Characteristics and outcomes of COVID-19 patients with IPF: A
multi-center retrospective study
Aykut Cillia,*, Ismail Hantab, Fatih Uzera, Funda Coskunc, Can Sevincd, Pelin Pınar Denizb,
Mehmet Parlaka, Ersoy Altunokb, Kemal Can Tertemizd, Ahmet Ursavasc
Department of Respiratory Disease, Akdeniz University, Antalya, Turkey
Department of Respiratory Disease, Cukurova University, Adana, Turkey
Department of Respiratory Disease, Uludag University, Bursa, Turkey
Department of Respiratory Disease, Dokuz Eylul University, Izmır, Turkey
A R T I C L E
I N F O
Received 16 November 2021
Revised 18 February 2022
Accepted 25 February 2022
Available online 3 March 2022
Interstitial lung disease
Idiopathic pulmonary ﬁbrosis
A B S T R A C T
Background: There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID19) infection in patients with idiopathic pulmonary ﬁbrosis (IPF). The objective of this study is to describe
the characteristics and outcomes of IPF patients conﬁrmed COVID-19 infection.
Methods: In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with
known IPF and a COVID-19 diagnosis were identiﬁed. Demographic and clinical outcome data were
abstracted through a review of electronic medical records.
Results: Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65§
10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in
thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the
hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was signiﬁcantly associated with lower DLCO/VA, long term oxygen therapy and
consolidation ﬁnding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated
with hospitalization or mortality.
Conclusions: IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain
key to protect IPF patients.
© 2022 SPLF and Elsevier Masson SAS. All rights reserved.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.